By Stephen Nakrosis
Protalix BioTherapeutics' Chief Financial Officer Eyal Rubin plans to leave the company and has given his six months notice.
Rubin is leaving to pursue other opportunities, Protalix said Wednesday.
The biopharmaceutical said Rubin has been CFO since 2019, and before that worked at BrainStorm Cell Therapeutics and Teva Pharmaceutical Industries.
During the six month period, Rubin will continue to serve in his current role and provide transition services to Protalix.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 23, 2025 18:14 ET (22:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。